Suraminnatrium

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Warnung

• Gefahrenhinweise

  H317：Kann allergische Hautreaktionen verursachen.

• Sicherheit

  P261：Einatmen von Staub vermeiden.

  P272：Kontaminierte Arbeitskleidung nicht außerhalb des Arbeitsplatzes tragen.

  P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

  P302+P352：BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.

  P321：Besondere Behandlung

  P333+P313：Bei Hautreizung oder -ausschlag: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

  P363：Kontaminierte Kleidung vor erneutem Tragen waschen.

  P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

Suramin sodium Chemische Eigenschaften,Einsatz,Produktion Methoden

• S-Sätze Betriebsanweisung:

  S22:Staub nicht einatmen.
  S24/25:Berührung mit den Augen und der Haut vermeiden.

• Beschreibung

  Introduced into therapy for the treatment of early trypanosomiasis in the 1920s, suramin, a bis-hexasulfonatednaphthylurea, is still considered to be the drug of choice for treatment of non-CNS-associated African trypanosomiasis.

• Chemische Eigenschaften

  White crystalline powder

• Verwenden

  Suramin sodium is a compound with a dyelike structure. Suramin is most effective against T. b. rhodesiense, but has also been used against T. b. gambiense infection. The compound causes side effects such as nausea, photophobia, and peripheral neuropathy which disappear shortly after conclusion of administration. Because the drug is unable to pass the bloodbrain barrier, prompt treatment of patients is essential. Suramin in combination with tryparsamide is an alternative that has been investigated.

• Verwenden

  antiviral

• Verwenden

  Sodium salt of Suramin, a hepatitis C virus NS3 helicase inhibitor. Also used in the treatment of arthritis due to problematic collagen.

• Definition

  ChEBI: Suramin sodium is an organic sodium salt that is the hexasodium salt of suramin. It is an FDA approved drug for African sleeping sickness and river blindness. It has a role as an antinematodal drug, a trypanocidal drug, an antineoplastic agent, an angiogenesis inhibitor, an apoptosis inhibitor, an EC 2.7.11.13 (protein kinase C) inhibitor, a GABA antagonist, a GABA-gated chloride channel antagonist, a purinergic receptor P2 antagonist and a ryanodine receptor agonist. It contains a suramin(6-).

• Indications

  Suramin (Germanin) is a derivative of a nonmetallic dye whose antiparasitic mechanism of action is not clear. It appears to act on parasite specificα-glycerophosphate oxidase, thymidylate synthetase, dihydrofolate reductase, and protein kinase but not on host enzymes.

• Indications

  Suramin is widely used as a macrofilaricide in human onchocerciasis, and its action on microfilariae also is considerable. It also is useful in the treatment of the hemolymphatic stage of African trypanosomiasis. Early treatment of the infection with suramin clears trypanosomes from the blood and lymphatics within 30 minutes and keeps them clear for approximately 3 months. Suramin inhibits a number of filarial enzymes involved with carbohydrate metabolism as well as the production of adenosine triphosphate (ATP). It is 35 times more inhibitory to the dihydrofolate reductase of O. volvulus than to the same enzyme in human tissue. It is a potent inhibitor of reverse transcriptase, the DNA polymerase of retroviruses, and also has some effects on the infective and cytopathic effects of HIV. It is being evaluated as an anticancer drug, reducing pain and delaying progression in hormone-refractory prostate cancer. Its most significant toxicity has been the development of severe polyradiculoneuropathy.

• Antimicrobial activity

  Suramin has no significant trypanocidal activity in vitro, but is effective in animals infected with T. brucei. Trypanosomes take up suramin bound to plasma protein by a combination of fluid phase and receptor-mediated endocytosis. It acts synergistically with nitroimidazoles and eflornithine in the elimination of trypanosomes from CSF of infected mice.

• Acquired resistance

  Relapse rates of 30–50% have been recorded in Kenya and Tanzania but there is no evidence of resistant parasites. Stable resistance has been described in the related camel parasite Trypanosoma evansi.

• Pharmazeutische Anwendungen

  A sulfated naphthylamine formulated for intravenous administration. It is freely soluble in water. The dry powder is stable, but it is hygroscopic and unstable in solution.

• Pharmazeutische Anwendungen

  A complex symmetrical molecule originally developed in Germany in the early 1920s for the treatment of African trypanosomiasis. Its useful anthelmintic activity is restricted to O. volvulus and it has been used to achieve a radical cure of onchocerciasis by killing the adult worms. However, it is an extremely toxic drug and its use has become increasingly uncommon since ivermectin became available.

• Biologische Aktivität

  Non-selective P2 purinergic antagonist. Also blocks calmodulin binding to recognition sites and G protein coupling to G protein-coupled receptors. Anticancer and antiviral agent.

• Mechanism of action

  Suramin is not absorbed from the intestinal tract and is administered intravenously. Although the initial high plasma levels drop rapidly, suramin binds tightly to and is slowly released from plasma proteins, and so it persists in the host for up to 3 months. Suramin neither penetrates red blood cells nor enters the CNS. It is taken up by the reticuloendothelial cells and accumulates in the Kupffer cells of the liver and in the epithelial cells of the proximal convoluted tubules of the kidney. It is excreted by glomerular filtration, largely as the intact molecule.

• Pharmakokinetik

  Oral absorption: Poor
  C_max 1 g intravenous doses (6 doses at weekly intervals): 100 mg/L
  Plasma half-life: 44–54 days
  Volume of distribution: 20–80 L
  Plasma protein binding: >99%
  It is normally administered by slow intravenous infusion. It can be detected in blood for 3 months; plasma levels >100 mg/L were observed for several weeks after a 6-week course of treatment. No metabolism was observed and 80% was removed by renal clearance. Distribution to mononuclear phagocytes, especially liver macrophages, the adrenal glands and the kidney is high. It does not enter erythrocytes and penetrates the blood–brain barrier poorly.

• Clinical Use

  African sleeping sickness (early stage before CNS involvement) Onchocerciasis

• Clinical Use

  Suramin sodium is a high molecular-weight bisurea derivative containing six sulfonic acid groups as their sodium salts. It was developed in Germany shortly after World War I as a byproduct of research efforts directed toward the development of potential antiparasitic agents from dyestuffs. The drug has been used for more than half a century for the treatment of early cases of trypanosomiasis. Not until several decades later, however, was suramin discovered to be a long-term prophylactic agent whose effectiveness after a single intravenous injection is maintained for up to 3 months. The drug is tightly bound to plasma proteins, causing its excretion in the urine to be almost negligible. Tissue penetration of the drug does not occur, apparently because of its high molecular weight and highly ionic character. Thus, an injected dose remains in the plasma for a very long period. Newer, more effective drugs are now available for short-term treatment and prophylaxis of African sleeping sickness. Suramin is also used for prophylaxis of onchocerciasis. It is available from the CDC.

• Clinical Use

  Suramin is used primarily to treat African trypanosomiasis, for which it is the drug of choice. It is effective in treating disease caused by Trypanosoma gambiense and T. rhodesiense but not T. cruzi (Chagas’ disease). It can be used alone prophylactically or during the initial hemolymphatic stages of the disease. Later stages, particularly those involving the CNS, are more commonly treated with a combination of suramin and the arsenical melarsoprol.
  When CNS involvement occurs, the poor penetration of suramin and pentamidine into the CSF requires alternative forms of chemotherapy, such as melarsoprol in combination with suramin. In treating Onchocerca volvulus infections, suramin kills adult worms and is an alternative to ivermectin. Suramin is used after initial treatment with diethylcarbamazine, which is used to kill the microfilariae. It produces favorable results in pemphigus and prolongs the time to disease progression in hormone-refractory prostate cancer.

• Nebenwirkungen

  It is important to test for drug sensitivity by administering a small (200 mg) dose by slow intravenous injection before giving the full amount of suramin. Since adverse reactions occur with greater frequency and severity among the malnourished, greater caution is necessary for patients with advanced trypanosomiasis. An acute reaction in sensitive individuals results in nausea, vomiting, colic, hypotension, urticaria, and even unconsciousness; fortunately, this reaction is rare. Rashes, photophobia, paresthesias, and hyperesthesia may occur later; these symptoms may presage peripheral neuropathy. Mild albuminuria is not uncommon, but hematuria with casts suggests nephrotoxicity and the need to stop treatment.

• Nebenwirkungen

  Suramin is toxic, especially in malnourished patients. A test dose of 200 mg has been recommended. Immediate febrile reactions (nausea, vomiting, loss of consciousness) can be avoided by slow intravenous administration. Intramuscular or subcutaneous injections are painful and irritating, and can be followed by fever and urticaria. Anaphylactic shock occurs in fewer than 1 in 2000 patients. Delayed reactions include renal damage, exfoliative dermatitis, anemia, leukopenia, agranulocytosis, jaundice and diarrhea.

• Synthese

  Suramin, a hexasodium salt of [8,8ˉ carbonyl-bis-[imino-3,1-phenylencarbonylimino(4-methyl-3,1-phenylen)carbonylimino]]-bis-1,3,5-naphthalintrisulfonic acid (37.4.13), can be made by reacting 1-aminonaphthalene-3,6,8-trisulfonic acid with 4-methyl-3-nitrobenzoyl chloride to make a nitrobenzoic derivative (37.4.8). The nitro group in this compound is reduced by activated iron to an amino derivative (37.4.9), which is acylated by m-nitrobenzoylchloride to make a new nitroderivative, m-nitrobenzoyl-(4-methyl-3-aminobenzoyl)-1-aminonaphthalene-3,6,8-trisulfonic acid (37.4.10).
  This is once again reduced to the amine (37.4.11) in the same manner. Reacting the resulting product with phosgene makes [8,8-carbonyl-bis-[imino-3,1-phenylencarbonylimino(4-methyl-3,1-phenylen]-carbonylimino]-bis-1,3,5-naphthalenetrisulfonic acid (37.4.12), which upon being treated with sodium hydroxide gives suramin.

  

Suramin sodium Upstream-Materialien And Downstream Produkte

Suraminnatrium Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(269)Suppliers

129-46-4, Suramin sodium Verwandte Suche: